A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

The US-based company’s Stop-HS1 (NCT05620823) and Stop-HS2 (NCT05620836) trials hit their primary endpoints with both doses ...